Reports that a drug that treats toxoplasmosis went from $13.50 to $750 per pill caused outrage among medical experts, politicians, and the public.
A complaint filed with the Massachusetts Commission Against Discrimination accuses Mutual of Omaha of denying long-term care insurance to a man taking HIV medications.
A new study found that no one taking pre-exposure prophylaxis to prevent HIV became infected over the course of three years. But the rates of other STIs were still high.
Researchers from France recently presented the results of a case in which a girl born with HIV who was treated early in life has remained in remission without medication for 12 years. Experts are excited but cautious because similar cases have ended with HIV being detected in patients blood again.
Although strong policies provide important backing for schools’ decisions about curricula, they do not automatically translate into implementation at the classroom level.
A small human study has found that infusing a person’s blood with HIV antibodies can cut the amount of virus in their body even if they are not taking antiretroviral drugs.
One in four people living with HIV in the United States are women. So why is HIV prevention medication overwhelmingly only targeted at men who have sex with men?
Thanks to restrictive laws and limited health-care options, halting the spread of HIV and hepatitis C is often a losing battle—one that puts women substance users in particularly high danger.
On January 7, the Microbicide Trials Network (MTN) made the welcome announcement that it had added the first clinical trial of a microbicide for women living with HIV to its research portfolio.
UNAIDS released a report in advance of World AIDS Day with hopeful news about the epidemic: there has been nearly a 50 percent reduction in new infections across 25 low and middle income countries. As UNAIDS Executive Director Michel Sidibe put it, “We are moving from despair to hope.” Young people are at the center of that success.